The Power of DNA

Extending the power of DNA into small molecule drug generation

Empress makes small molecule drug discovery more predictable and efficient by accessing superior drug starting points from human chemistry encoded in DNA.

A vast and untapped opportunity

The solution to faster drug discovery is inside of us

The amount of genomic material encoding instructions for the biosynthesis of small molecules in the metagenome is equivalent to ~50% of the human genome.

Until now, this universe has never been systematically explored, mapped to therapeutic opportunities and mined for new medicines.

Human chemistry encoded in DNA

DNA encodes RNA, which in turn encodes proteins that then synthesize or modify small molecules.

Advances in genomics, AI, and synthetic biology now allow us to “read” DNA sequence data sourced from patient samples and systematically identify, decode, and use these biosynthetic instructions to make small molecule drugs fast.

Start with the last experiment first

Chemistry co-evolved with biology. The molecules made inside our bodies today are the sum result of innumerable evolutionary experiments across millennia.

Biosynthetic DNA reveals instructions for making potent, selective chemistries that are human compatible and important for maintaining health and treating or preventing disease.

DNA encodes proteins that synthesize small molecules



The biosynthetic metagenome is equivalent to 50 percent of the human genome.


DNA encodes proteins, specifically enzymes, that make or modify small molecules.


Billions of small molecules drive millions of chemical reactions in the human body to maintain health.

Make drugs fast

Created by co-evolution, refined by life

Human compatibility

We sample from millions of small molecules that are made, modified, and play important roles within the human body.

Broad therapeutic potential

Comparing patient data from health and disease allows us to map chemistry to therapeutic potential. These molecules can be found throughout the body, showing the potential to address a wide variety of diseases.

Drug-like characteristics

Our platform filters for important features like potency, selectivity, and dose-dependent therapeutic activity.